Zoledronic Acid as a Novel Dual Blocker of KIR6.1/2-SUR2 Subunits of ATP-Sensitive K
KATP channels
adverse drug reactions
musculoskeletal and cardiovascular
zoledronic acid
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
27 Aug 2021
27 Aug 2021
Historique:
received:
14
07
2021
revised:
06
08
2021
accepted:
17
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Zoledronic acid (ZOL) is used as a bone-specific antiresorptive drug with antimyeloma effects. Adverse drug reactions (A.D.R.) are associated with ZOL-therapy, whose mechanics are unknown. ZOL is a nitrogen-containing molecule whose structure shows similarities with nucleotides, ligands of ATP-sensitive K
Identifiants
pubmed: 34575427
pii: pharmaceutics13091350
doi: 10.3390/pharmaceutics13091350
pmc: PMC8465290
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmacol Res. 2019 Sep;147:104343
pubmed: 31279830
Biochem Soc Trans. 2006 Apr;34(Pt 2):243-6
pubmed: 16545085
J Am Chem Soc. 2018 Jun 20;140(24):7568-7578
pubmed: 29787268
Mayo Clin Proc. 2008 Sep;83(9):1032-45
pubmed: 18775204
Cell. 2017 Jan 12;168(1-2):101-110.e10
pubmed: 28086082
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
J Biol Chem. 2017 Oct 20;292(42):17387-17398
pubmed: 28842488
Electrophoresis. 1997 Dec;18(15):2714-23
pubmed: 9504803
J Physiol. 2010 Mar 1;588(Pt 5):773-84
pubmed: 20064856
Biochem Pharmacol. 2014 Sep 15;91(2):266-75
pubmed: 24998494
Protein Cell. 2018 Jun;9(6):553-567
pubmed: 29594720
Pflugers Arch. 2010 Jul;460(2):295-306
pubmed: 20033705
Neuromuscul Disord. 2006 Jan;16(1):39-45
pubmed: 16368240
Cancers (Basel). 2019 Feb 11;11(2):
pubmed: 30754651
CNS Neurol Disord Drug Targets. 2021 Jan 18;:
pubmed: 33463481
Nat Protoc. 2016 May;11(5):905-19
pubmed: 27077332
Biochim Biophys Acta. 2010 Sep;1804(9):1695-712
pubmed: 20433957
J Mol Graph. 1990 Mar;8(1):52-6, 29
pubmed: 2268628
Bone. 2021 Feb 22;:115901
pubmed: 33631354
EXS. 2000;88:215-31
pubmed: 10803381
Osteoporos Int. 2008 Jun;19(6):733-59
pubmed: 18214569
Pediatrics. 2007 Mar;119 Suppl 2:S150-62
pubmed: 17332236
Anal Biochem. 2012 Feb 1;421(1):158-63
pubmed: 22085443
Eur J Med Chem. 2018 Oct 5;158:184-200
pubmed: 30216851
Int J Mol Sci. 2019 May 07;20(9):
pubmed: 31067750
Cancer. 2000 Jun 15;88(12 Suppl):2961-78
pubmed: 10898340
Cell Mol Life Sci. 2021 Feb;78(4):1501-1522
pubmed: 32623480
Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1118-23
pubmed: 16418275
Cochrane Database Syst Rev. 2017 Dec 18;12:CD003188
pubmed: 29253322
Circ Res. 2013 Mar 29;112(7):1059-72
pubmed: 23538276
Breast Cancer Res. 2011 Apr 06;13(2):207
pubmed: 21586099
Biochem Pharmacol. 2016 Jan 15;100:112-32
pubmed: 26616220
J Chem Theory Comput. 2017 Jun 13;13(6):3031-3048
pubmed: 28430426
Pharmacol Res Perspect. 2016 Jan 15;4(1):e00197
pubmed: 26977294
Front Pharmacol. 2020 Nov 30;11:604885
pubmed: 33329006
Biochem J. 2014 Jul 15;461(2):305-14
pubmed: 24779955
N Engl J Med. 2008 Jul 17;359(3):316-7; author reply 317-8
pubmed: 18635442
Eur J Haematol. 2014 Mar;92(3):181-8
pubmed: 24330023
J Cardiovasc Pharmacol Ther. 2021 Jul;26(4):341-348
pubmed: 33403858
Front Neurosci. 2019 Oct 22;13:1122
pubmed: 31695594
J Clin Invest. 1999 Mar;103(5):675-82
pubmed: 10074484
Pharmacol Res Perspect. 2014 Feb;2(1):e00028
pubmed: 25505577
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
pubmed: 15173273
Mayo Clin Proc. 2009 Jul;84(7):632-7; quiz 638
pubmed: 19567717
Protein Sci. 2014 Jan;23(1):47-55
pubmed: 24265211
Curr Protoc Bioinformatics. 2006 Oct;Chapter 5:Unit-5.6
pubmed: 18428767
Biomolecules. 2020 Dec 30;11(1):
pubmed: 33396658
Methods Mol Biol. 2012;816:19-29
pubmed: 22130919
J Clin Med. 2019 Dec 02;8(12):
pubmed: 31810296
Diabetes Obes Metab. 2012 Feb;14(2):130-8
pubmed: 21923736
J Transl Med. 2013 Dec 11;11:303
pubmed: 24330728
Oncologist. 2004;9 Suppl 4:3-13
pubmed: 15459425